RCC, weakly expressed in clear-cell RCC and negatively expressed in papillary RCC.
AB138. Experience on thulium laser treatment in transurethral resection of bladder tumor

Xiuguo Gan, Ruihua An
Harbin Medical University, Harbin 150081, China Objective: To study the safety and efficacy of thulium laser treatment of bladder cancer. Methods: Thulium laser surgery system was used for the treatment of 45 cases of bladder cancer patients, including 33 cases of single tumor, 12 cases of multiple tumors. Tumor diameter were 5-25 mm. Tumor pathology were bladder transitional cell carcinoma, clinical stage at T1-T2. Results: All the surgery was successfully completion. Operation time was 10-35 minutes. Blood loss was 0-5 mL. None of bladder has perforation, water intoxication, urinary leakage or postoperative bleeding. All of the patients had received immediate intravesical chemotherapy within 0.5 hours, and to maintain bladder chemotherapy. All had catheter indwelled 5 to 7 days. Patients were followed up 1 year, no recurrence of the surgical area. Conclusions: Thulium laser surgery system for the transurethral treatment of bladder cancer within stage T2 is safe and effective. Objective: To investigate whether low-dose BCG treatment can reduce the side effects while maintaining efficacy for patients with NMIBC when compared with standard dose BCG treatment. Methods: A comprehensive literature search of PubMed, EMBASE, CINAHL, LILACS and CENTRAL databases was conducted to identify relevant randomized controlled trials (RCT) or quasi-randomized controlled trials (qRCT) that have assessed the efficacy of low and standard dose BCG therapy for patients with NMIBC. Systematic review and meta-analysis were performed according to preferred reporting items for systematic reviews and meta-analysis criteria. Results: Six RCTs and two qRCTs were eligible for metaanalysis. Low-dose BCG instillation was not inferior to reduce the risk of bladder tumor recurrence [hazard ratio (HR), 1.15; 95% confidence interval (CI), 1.00-1.31; P=0.05], meanwhile no difference was found regarding tumor progression (HR =1.08; 95% CI, 0.83-1.42; P=0.57). However, low-dose BCG provided a significantly lower incidence of overall side effects (RR =0.75; 95% CI, 0.60-0.94; P=0.01), systemic side effects (RR =0.57; 95% CI, 0.34-0.97; P=0.04), severe side effects (RR =0.52; 95% CI, 0.36-0.74; P=0.0003) and withdrawal due to BCG toxicity (RR =0.49; 95% CI, 0.26-0.91; P=0.02). In contrast, local side effects were comparable between low-dose and standard dose arms (RR =0.89; 95% CI, 0.73-1.08; P=0.24). Conclusions: Low-dose BCG instillation significantly reduces the incidence of overall side effects, especially severe and systemic symptoms in patients with NMIBC, while the oncological control efficacy of low-dose BCG is not inferior to standard dose BCG. Further studies with stratification using different risk factors at randomization are required to assess whether the efficacy of low-dose BCG is comparable to standard dose BCG for different risk of patients. Objective: To investigate the clinical efficacy of retropubic radical prostatectomy subsequent to neoadjuvant chemotherapy and neoadjuvant hormonal therapy in the treatment of local advanced prostate cancer and to evaluate its adverse effects and tolerance. Methods: Fourteen patients with local advanced prostate cancer from Feb. 2015 to Jan. 2016 were firstly given three cycles of neoadjuvant chemotherapy combined with neoadjuvant hormonal therapy (the 21 days regimen of docetaxel plus prednisone combined with goserelin acetate 3.6 mg/28 d), after that, retropubic radical prostatectomy with extended pelvic lymph node dissection was performed. The extent of extended lymph node dissection includes lymph nodes near external iliac vessel, obturator, internal iliac vessel and common iliac artery. The clinical features and short-term efficacy of these patients were investigated prospectively. All patients excluded severe medical complications, bone metastasis, visceral metastasis, and their life expectancy >10 years. Recording their age, initial clinical stage, initial Gleason grade, initial PSA value, PSA value after neoadjuvant therapy, operative time, blood loss volume during operation, postoperative pathological stage, lymph node metastasis status, PSA value at 1 month after operation, PSA value at 3 month after operation and the recovery time of urinary continence. Only using 0-1 pad/24 h is the criterion of continence recovery. Results: The average age of 14 patients was 64.3 (range, 58-72) years. One of whose Gleason score was 3+3=6, two of whose Gleason score were 3+4=7, four of whose Gleason score were 4+3=7, one of whose Gleason score was 5+3=8, two of whose Gleason score were 5+4=9. The mean PSA value before combined neoadjuvant therapy was 72.6 (range, 55.8-119) ng/mL. Seven of whose clinical stage were cT3bN0M0, two of whose clinical stage were cT3bN1M0, three of whose clinical stage were cT4N0M0, two of whose clinical stage were cT4N1M0. Neutropenia (neutrophil count <2.0×10 9 /L) occurred in 11 patients during the time of combined neoadjuvant therapy, all of them recovered after treated by G-CSF; hepatic impairment occurred in one patient who underwent two cycles of DP chemotherapy regimen, the patient's liver function recovered after liverprotecting treatment and then went on the 3th cycle of DP regimen for continued treatment. One patient's date of surgery (radical prostatectomy) was brought forward after two weeks of combined neoadjuvant therapy for severe gastrointestinal reaction. The mean preoperative PSA value dropped to 2.7 (range, 0.48-7.66) ng/mL after combined neoadjuvant therapy. The mean operative time
